GAI, Global-Tech Advanced Innovations Inc.
** On its third quarter fiscal 2012, GAI posted net sales of $44.2 million, an approximately 81% increase year over year, and net income of $3.3 million, or $1.09 per share, compared to a net loss of $1.5 million, or $0.48 per share in the same period the prior year.
For the nine months ended December 31, 2011, GAI posted net sales of $103.1 million, up approximately 37% when compared to $75.2 million in the corresponding nine-month period in fiscal 2011, and net income of $2.9 million, or $0.97 per share, compared to a net loss of $1.5 million, or $0.51 per share, in the same period the prior year.
GAI is a holding company, owning subsidiaries that manufacture and market a diversified portfolio of products, such as complementary metal oxide semiconductor (CMOS) and camera modules (CCMs). The primary focus of GAI's subsidiaries is to develop and market high-quality products for the communications industry in China and export such products to markets in North America, Europe, and other countries throughout the world.
More about GAI at www.global-webpage.com
PRXI, Premier Exhibitions Inc.
One hundred years on the anniversary of Titanic's maiden voyage, there will be an unprecedented auction of artifacts recovered from the wreck site of the legendary ocean liner, and related intellectual property and intangibles.
PRXI recently reported that due to the level of interest in its auction of the Titanic artifact collection and the late entry of additional potential bidders, the Company has extended the deadline for the submission of bids to 5 p.m. on Monday, April 9, 2012. As stated previously, the Company will announce additional information on April 11, 2012.
Guernsey's will be offering all of the assets and rights of RMS Titanic, Inc., a division of PRXI, which for 18 years has served as steward and salvor-in-possession of Titanic and its wreck site.
These assets include the complete collection of more than 5,000 artifacts, as well as other extraordinary intangible assets, in the first and only sale of objects that have been recovered from the wreck site of Titanic two and a half miles below the ocean's surface.
Consisting of items owned by RMS Titanic, Inc. and recovered from the Titanic wreck site, the auction will comprise all of the artifacts to be sold as one single collection. The sale is subject to certain covenants and conditions to ensure the collection will be properly maintained and available for public display.
Also included in the sale are important archeological assets created by RMS Titanic, Inc. on the eight research and recovery missions it has conducted at the Titanic site more than 12,000 feet below the ocean surface. These assets include, among other things, video of the dives, 3-D images of the ship, and the first and only comprehensive survey map of the wreck site. The purchaser may also have the opportunity to assume the role of steward of the Titanic, to protect and preserve the wreck site for future generations.
PRXI's wholly owned subsidiary RMS Titanic, Inc. is the only company permitted by law to recover objects from the wreck of Titanic. The Company was granted Salvor-In-Possession rights to the wreck of Titanic by a United States Federal Court in 1994 and has conducted seven research and recovery expeditions to Titanic recovering more than 5,500 artifacts.
In the summer of 2010, RMS Titanic, Inc., conducted a ground-breaking expedition to Titanic 25 years after its discovery, to undertake innovative 3D video recording, data gathering and other technical measures so as to virtually raise Titanic, preserving the legacy of the Ship for all time.
PRXI is a leading presenter of museum quality exhibitions throughout the world. PRXI is a recognized leader in developing and displaying unique exhibitions for education and entertainment including "Titanic: The Artifact Exhibition", "BODIES ... The Exhibition" and "Dialog in the Dark".
More about PRXI at www.prxi.com.
LLY, Eli Lilly and Company
** LLY and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of LLY, reported the FDA approval of Amyvid(TM), a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.
Amyvid is a radioactive diagnostic agent tagged with a radioisotope called fluorine-18. Once Amyvid is injected into a vein, it travels through the bloodstream and into the brain, binding to amyloid plaques, a hallmark characteristic of Alzheimer's Disease, and is detected using positron emission tomography (PET) scan images of the brain.
A negative Amyvid scan indicates sparse to no amyloid plaques are currently present, which is inconsistent with a neuropathological diagnosis of Alzheimer's Disease and reduces the likelihood that a patient's cognitive impairment is due to Alzheimer's Disease. A positive Amyvid scan indicates moderate to frequent amyloid plaques are present; this amount of amyloid plaque is present in patients with Alzheimer's Disease, but may also be present in patients with other types of neurologic conditions and in older people with normal cognition.
It's important to note that Amyvid is an adjunct to other diagnostic evaluations. A positive Amyvid scan does not establish a diagnosis of Alzheimer's Disease, or other cognitive disorder. Additionally, the safety and effectiveness of Amyvid have not been established for predicting development of dementia or other neurologic condition, or monitoring responses to therapies.
Alzheimer's Disease is one of several possible causes of cognitive decline. Alzheimer's Disease and other causes of cognitive impairment share many overlapping symptoms including memory, visuospatial ability, executive function, behavior and language deficiencies.
Amyvid images should be interpreted only by readers who have successfully completed Amyvid reader training.
LLY is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.
More about LLY at www.lilly.com.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.